DiaSorin and QIAGEN sign collaboration to expand liaison test menu through adoption of select QIAGEN assays
June 22, 2017 – Saluggia, Italy; Hilden, Germany, and Germantown, Maryland - DiaSorin (FTSE Italy Mid Cap: DIA) and QIAGEN (NASDAQ: QGEN; Frankfurt Stock Exchange: QIA) announced today a new collaboration to develop new tests for DiaSorin’s LIAISON family of analyzers based on a review and selection process involving QIAGEN’s assay technologies.
The adoption of select assays from QIAGEN’s portfolio for use on DiaSorin’s fully-automated detection systems is expected to strengthen the LIAISON menu, which is targeted primarily at hospital laboratories, and create benefits for these customers, in particular those using the full automation and high-throughput features of the LIAISON XL version.
Assays under consideration for adoption on LIAISON include select QIAGEN tests that can be applied to the LIAISON sample processing and detection capabilities.
Carlo Rosa, Chief Executive Officer of DiaSorin Group, commented: “I’m really excited about this market opportunity that sees DiaSorin joining forces with QIAGEN as a leading global provider of molecular testing solutions. This collaboration opens to us the opportunity to add content and address very significant markets while leveraging on our LIAISON technology. We believe this partnership will help us to continue our successful story as a leading immunodiagnostic company providing reliable solutions to laboratories all around the world.”
Peer M. Schatz, Chief Executive Officer of QIAGEN N.V, commented: “Our assay technologies at QIAGEN offer unique ways to detect and assess various diseases while in various stages of development, and this is enabling QIAGEN to help customers around the world improve the lives of patients. This non-exclusive collaboration with DiaSorin enables us to expand the use of QIAGEN tests to include DiaSorin’s widely placed automation systems with a strong presence in hospital laboratories and DiaSorin’s great experience in promoting differentiated, value-added assays.”
Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD “diagnostics specialist”. For more information, please visit www.diasorin.com
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of June 30, 2017, QIAGEN employed approximately 4,600 people in over 35 locations worldwide.
Further information can be found at http://www.qiagen.com.
QIAGEN Forward-looking statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).